silybin has been researched along with Non-alcoholic Fatty Liver Disease in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 13 (46.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Fei, W; Gao, Z; Ren, L; Wang, Y; Yang, L; Yu, X; Zhang, H; Zhao, H; Zhen, Y | 1 |
| Ezhilarasan, D; Lakshmi, T | 1 |
| Che, YS; Cui, JJ; Du, P; Guo, HH; Jiang, JD; Li, R; Ma, XL; Ren, L; Tang, R; Wang, HL; Wang, LL; Wang, YN; Yan, PJ; Yu, HY; Yu, XY; Zheng, WS | 1 |
| Shu, S; Wang, H; Wang, Q; Xu, Z | 1 |
| Cao, L; Ding, C; Hao, H; He, T; Shuai, Y; Wang, Y; Wu, J; Xie, Z; Xu, W; Zhang, C; Zhang, S | 1 |
| Cao, Z; Fang, C; Han, D; Han, J; Lei, Y; Luo, H; Ma, Y; Pan, J; Pan, Z; Qu, N; Zhang, J; Zhang, Z | 1 |
| Cui, J; Jiang, J; Li, R; Ma, X; Ren, L; Wang, L; Yu, H; Yu, X; Zhang, W | 1 |
| Chen, SY; Pang, XC; Suguro, R; Xie, Y; Yuan, ZW; Zhu, YZ | 1 |
| Cossiga, V; Dallio, M; Di Sarno, R; Federico, A; Gravina, AG; Lama, S; Loguercio, C; Masarone, M; Morisco, F; Persico, M; Stiuso, P; Tuccillo, C | 1 |
| Aa, J; Sun, R; Wang, G; Wei, Q; Xie, Y; Xu, D; Zhang, B | 1 |
| Elkhateb, IT; Mohye Eldeen, R; Mousa, A; Soliman, Y | 1 |
| Chen, S; Li, Y; Liu, Q; Ren, L; Song, G; Wang, Y; Yang, L; Zhang, H | 1 |
| Cheng, LH; Cui, S; Ge, CL; Guo, YT; Hao, HP; He, QX; Pan, XJ; Wang, GJ; Wang, H; Yan, TT; Zhang, PF; Zhou, JY | 1 |
| Chen, J; Chen, Z; Yang, XD; Yang, YY; Ye, L | 1 |
| Cui, CX; Deng, JN; Fan, JY; Han, JY; Liu, YY; Mu, HN; Sun, HY; Wang, YH; Yan, L | 1 |
| Avola, R; Barbagallo, I; Cinà, D; Currenti, W; D'Orazio, N; Galvano, F; Godos, J; Lembo, V; Li Volti, G; Morisco, F; Salomone, F | 1 |
| Kang, BS; Kwon, OS; Lee, DE; Lee, DS; Lee, HS; Lee, SJ; Nam, MJ; Park, JW | 1 |
| Ou, Q; Wang, S; Weng, Y; Wu, X; Zhang, F; Zhao, Y; Zhou, J | 1 |
| Anfuso, B; Giraudi, PJ; Rosso, N; Tiribelli, C | 1 |
| Baldini, F; Grasselli, E; Oliveira, PJ; Portincasa, P; Sardão, VA; Vecchione, G; Vergani, L; Voci, A | 1 |
| Gao, X; Hu, P; Li, C; Yang, X; Yao, J; Zhi, M | 1 |
| Cao, M; Hai, J; Pei, S; Wang, J; Zhang, Q; Zhang, Y | 1 |
| Abenavoli, L; Bellentani, S | 1 |
| Abenavoli, L; Accattato, F; Foti, D; Greco, M; Gulletta, E; Luzza, F; Milic, N; Nazionale, I; Peta, V | 1 |
| Hu, WY; Li, XX; Ma, XH; Sun, H; Sun, TT; Zhou, WY | 1 |
| Minhu, C; Yao, J; Zhi, M | 1 |
| Bucchieri, F; Bugianesi, E; Galvano, F; Li Volti, G; Mangiameli, A; Marino Gammazza, A; Marino, A; Parola, M; Paternostro, C; Salamone, F; Tibullo, D | 1 |
| Barbagallo, I; Cappello, F; Galvano, F; Li Volti, G; Mangiameli, A; Salamone, F | 1 |
1 review(s) available for silybin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Topics: Antioxidants; Humans; Liver; Liver Neoplasms; NF-kappa B; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Resveratrol; Silybin; Silymarin | 2022 |
3 trial(s) available for silybin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Danshao Shugan Granule therapy for non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Humans; Liver; Malondialdehyde; Medicine, Chinese Traditional; Mice; NF-kappa B; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Superoxide Dismutase; Triglycerides | 2022 |
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.
Topics: Adult; Aged; Biomarkers; Body Weight; Cytokines; Drug Therapy, Combination; Endothelial Cells; Female; Humans; Insulin Resistance; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silybin; Vitamin D; Vitamin E | 2019 |
Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease.
Topics: Adult; Biomarkers; Body Mass Index; Cholesterol; Diet, Mediterranean; Dietary Supplements; Humans; Italy; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Overweight; Phosphatidylcholines; Prospective Studies; Silybin; Silymarin; Time Factors; Treatment Outcome; Triglycerides; Vitamin E; Waist Circumference | 2015 |
24 other study(ies) available for silybin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.
Topics: Animals; Chromatography, Liquid; Glucose; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phosphatidate Phosphatase; Proteins; Proteomics; Silybin; Tandem Mass Spectrometry | 2022 |
Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis.
Topics: Animals; Cricetinae; Cyclodextrins; Diet, High-Fat; Homeostasis; Humans; Liver; Non-alcoholic Fatty Liver Disease; Prebiotics; Silybin | 2022 |
Polyunsaturated fatty acids drive neutrophil extracellular trap formation in nonalcoholic steatohepatitis.
Topics: Animals; Disease Models, Animal; Extracellular Traps; Fatty Acids, Unsaturated; Inflammation; Mice; Neutrophils; Non-alcoholic Fatty Liver Disease; Silybin | 2023 |
Tiaogan Jiejiu Tongluo Formula attenuated alcohol-induced chronic liver injury by regulating lipid metabolism in rats.
Topics: Animals; Cholesterol, LDL; Ethanol; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Rats, Sprague-Dawley; Silybin; Sterol Regulatory Element Binding Protein 1; Superoxide Dismutase | 2023 |
Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.
Topics: Animals; Berberine; Fatty Acids; Lipid Metabolism; Lipids; Liver; Mice; Non-alcoholic Fatty Liver Disease; Silybin | 2024 |
Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism.
Topics: Animals; Flavones; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Protective Agents; Silybin | 2020 |
Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model.
Topics: Animals; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Lipid Metabolism; Liver; Male; Metabolomics; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Silybin; Taurochenodeoxycholic Acid | 2020 |
Accidentally discovered high INR in pregnancy unmasks an inherited factor VII (FVII) deficiency that is paradoxically associated with thrombotic tendency.
Topics: Adult; Antineoplastic Agents, Phytogenic; Cesarean Section; Factor VII Deficiency; Female; Humans; International Normalized Ratio; Lupus Coagulation Inhibitor; Non-alcoholic Fatty Liver Disease; Plasma; Pregnancy; Pregnancy Complications, Hematologic; Silybin; Thrombophilia; Venous Thrombosis | 2021 |
Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An
Topics: Acetyl-CoA Carboxylase; Animals; Fatty Acid Synthases; Gene Expression Regulation; Hep G2 Cells; Humans; Insulin Resistance; Lipid Metabolism; Liver; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Silybin; Triglycerides | 2021 |
Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Topics: Animals; Choline; Diet; Lipid Metabolism; Liver; Methionine; Mice; Non-alcoholic Fatty Liver Disease; Oxazoles; PPAR alpha; Silybin; Tyrosine | 2021 |
Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1/NF-
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cell Survival; Choline Deficiency; Cytokines; Esculin; Fatty Acids, Nonesterified; Fibrosis; Hep G2 Cells; Hepatocytes; Humans; Inflammation; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Models, Animal; NF-kappa B; Non-alcoholic Fatty Liver Disease; RNA, Small Interfering; Signal Transduction; Silybin; Sirtuin 1 | 2021 |
Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Capsules; Cricetinae; Diet, High-Fat; Fatty Acids; Insulin; Lipogenesis; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Silybin; Silymarin; Triglycerides | 2017 |
Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.
Topics: Adenylate Kinase; Animals; Diet, High-Fat; Gene Expression Regulation, Enzymologic; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease; Obesity; Silybin; Silymarin; Sirtuin 1 | 2017 |
Silibinin Ameliorates
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; beta-N-Acetylhexosaminidases; Choline Deficiency; Humans; Inflammation; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; NF-kappa B; Non-alcoholic Fatty Liver Disease; Peroxiredoxins; Proteomics; RAW 264.7 Cells; Silybin; Silymarin | 2018 |
Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression; Lipid Metabolism; Liver Cirrhosis; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silybin; Treatment Outcome | 2018 |
Silybin Modulates Collagen Turnover in an In Vitro Model of NASH.
Topics: Cell Line; Cell Survival; Coculture Techniques; Collagen; Fatty Acids, Nonesterified; Hepatic Stellate Cells; Hepatocytes; Humans; Liver; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Non-alcoholic Fatty Liver Disease; Reactive Oxygen Species; Silybin | 2019 |
Excess fructose and fatty acids trigger a model of non‑alcoholic fatty liver disease progression in vitro: Protective effect of the flavonoid silybin.
Topics: Animals; Apoptosis; Cell Line; Fatty Acids; Fructose; Hepatocytes; Lipid Metabolism; Lipid Peroxidation; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Protective Agents; Rats; Silybin | 2019 |
Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver.
Topics: Animals; Antioxidants; Glucose Tolerance Test; Homeostasis; Insulin Resistance; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Sprague-Dawley; Silybin; Silymarin; Time Factors | 2013 |
Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cell Line; Cell Line, Tumor; Diet, High-Fat; Fatty Liver; Glucose; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Non-alcoholic Fatty Liver Disease; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Silybin; Silymarin | 2013 |
Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?
Topics: Animals; Fatty Liver; Humans; Liver; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Extracts; Plants, Medicinal; Silybin; Silybum marianum; Silymarin; Treatment Outcome | 2013 |
Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice.
Topics: Animals; Camellia sinensis; Disease Models, Animal; Humans; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Plant Extracts; Silybin; Silymarin; Sterol Regulatory Element Binding Protein 1; Tea; Transcription Factors | 2017 |
Effect of silybin on high-fat-induced fatty liver in rats.
Topics: Animals; Antioxidants; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Fatty Liver; Homeostasis; Hypoglycemic Agents; Insulin Resistance; Lipid Peroxidation; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Silymarin; Thiazolidinediones | 2011 |
Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis.
Topics: Alanine Transaminase; Analysis of Variance; Animals; Antioxidants; Choline Deficiency; Cytokines; Diet; Fatty Liver; Gene Expression; Glutathione; Insulin Resistance; Isoprostanes; JNK Mitogen-Activated Protein Kinases; Liver; Male; Methionine; Mice; Myocardium; Nitrates; Nitrites; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phosphorylation; Silybin; Silymarin; Statistics, Nonparametric | 2012 |
Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Choline Deficiency; Disease Models, Animal; Fatty Liver; Homeostasis; Lipid Metabolism; Liver; Male; Methionine; Mice; Mice, Obese; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Silybin; Silymarin; Translational Research, Biomedical | 2012 |